Physician profile
Pedro T Ramirez
NPI 1598847972
$42,039.84
in general payments reported to CMS, 2019-2025
20 companies · $33K in 2025
The $33K reported for 2025 was more than what 96% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $4,150 · 2022: $425 · 2023: $680 · 2024: $2,406 · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Travel and Lodging: $6,960 · Food and Beverage: $3,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,350.00 |
| Travel and Lodging | $6,960.01 |
| Food and Beverage | $3,868.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $23,999.45 | 2024-2025 | Megadyne |
| Merck Sharp & Dohme LLC | $8,195.38 | 2019-2025 | Lynparza, Keytruda |
| Medical Device Business Services, INC. | $6,147.88 | 2019-2025 | Enseal |
| Biotissue Holdings INC. | $1,665.00 | 2025 | |
| Baxter Healthcare | $712.11 | 2024-2025 | Perclot, Seprafilm, Floseal |
| Stryker Corporation | $214.69 | 2023 | Spy-Phi System |
| Intuitive Surgical, INC. | $177.26 | 2019-2025 | |
| Dilon Technologies, INC. | $173.87 | 2025 | Hemoblast Bellows |
| Ethicon US, LLC | $171.64 | 2024 | Enseal, Harmonic, Ethicon |
| Tempus Ai, INC | $136.97 | 2024 | |
| Abbvie INC. | $125.00 | 2025 | |
| Glaxosmithkline, LLC. | $111.87 | 2025 | Zejula |
| Conmed Corporation | $93.04 | 2019 | |
| Astellas Pharma US INC | $26.62 | 2024 | Veozah |
| Caris Mpi, INC. | $20.66 | 2025 | Mi Cancer Seek |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $18.58 | 2023 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $17.99 | 2025 | Lynparza |
| Genmab U.S., INC. | $17.24 | 2025 | Tivdak |
| Meditrina | $14.59 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.